Let's talk about upstream IBD.

Azuriya Pharma welcomes inquiries from physicians, investigators, potential pharma partners, and the investor community. Select the path that best matches your interest — your message routes to the right team member.

Send a Message

We respond within 2 business days.

First name *

Last name *

Email *

Organization

I am a…

Topic

Message *

I am requesting confidential materials and acknowledge that an NDA may be required before access to non-public information is granted.

By submitting this form you acknowledge Azuriya Pharma's privacy policy. We will only use your information to respond to your inquiry and will not share it with third parties.

Investors

Investor Relations

For investor inquiries, financing round information, and access to the data room.

[email protected] ↗

Partnerships

Business Development

For pharma partnership discussions, licensing opportunities, and strategic alliances around APX3330 and the Ref-1 platform.

[email protected] ↗

Clinical & Scientific

KOL & Clinical Inquiries

For gastroenterology KOLs, principal investigators interested in Phase 2a sites, and academic collaborators.

[email protected] ↗

General

General & Media

For all other inquiries including media and press.

[email protected] ↗

Follow Azuriya

Announcements, publications, and milestones appear first on LinkedIn.

LinkedIn →

Forward-Looking Statements

Information on this website contains forward-looking statements regarding Azuriya Pharma's clinical development plans, financing scenarios, and strategic milestones. Actual results may differ materially from those contemplated. APX3330 is an investigational compound and has not been approved by the FDA, EMA, or any other regulatory authority.

Privacy & Confidentiality

Azuriya Pharma does not share inquiries or contact information with third parties. Confidential materials (full investor package, data room) require execution of an NDA. For more information, see our privacy policy or contact [email protected].